Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2026-03-19 Director's Dealing
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Havron Avraham
Director's Dealing Classification · 1% confidence The document is a Form 3 filed with the U.S. Securities and Exchange Commission. Form 3 is the 'Initial Statement of Beneficial Ownership of Securities' required under Section 16(a) of the Securities Exchange Act of 1934. This form is used by directors, officers, and 10% shareholders to report their initial holdings of company securities. In the provided taxonomy, reports of personal share transactions or holdings by company directors and executives are classified as 'Director's Dealing' (DIRS).
2026-03-19 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Havron Avraham
Regulatory Filings Classification · 1% confidence The document is a short regulatory filing from Enlivex Therapeutics Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on FORM 3' and provides a filename 'Havron_FORM_3_isa.pdf'. Form 3 is a standard SEC filing used for reporting initial beneficial ownership by directors, officers, or principal shareholders. Since this document is a brief notification announcing the filing of a Form 3 (which is a type of Director's Dealing/Insider transaction report) rather than the full report itself, and it follows the 'Menu vs Meal' rule for announcements, it is classified as a Regulatory Filing (RNS) as it serves as a formal notification of a regulatory submission.
2026-03-19 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Hart Gili
Director's Dealing Classification · 1% confidence The document is a Form 3 filed with the SEC, which is the 'Initial Statement of Beneficial Ownership of Securities'. This form is used by directors, officers, and principal shareholders to report their initial holdings in a company's securities. In the provided classification schema, 'Director's Dealing' (DIRS) is the appropriate category for reports concerning share transactions or holdings by company directors and executives.
2026-03-19 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Hart Gili
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing from Enlivex Therapeutics Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on FORM 3' and provides a filename 'Gili_Hart_FORM_3_isa.pdf'. Form 3 is a standard SEC filing used to report initial beneficial ownership by directors, officers, or principal shareholders. Since this document is a brief notification announcing the filing of an attached report rather than the report itself, it falls under the Report Publication Announcement (RPA) category.
2026-03-19 English
Other Report or Announcement
Regulatory Filings Classification · 1% confidence The document is a Form S-8 Registration Statement filed with the U.S. Securities and Exchange Commission. Form S-8 is used by public companies to register securities to be offered to employees under employee benefit plans (in this case, the 'Global Share Incentive Plan (2019)'). Since this document type does not have a specific category in the provided list, it falls under the 'Regulatory Filings' (RNS) category, which serves as the fallback for miscellaneous filings.
2026-03-14 English
Other Report or Announcement
Report Publication Announcement Classification · 1% confidence The document is a short notification from Enlivex Therapeutics Ltd filed via the Israel Securities Authority (MAGNA system). It explicitly states 'Attached hereto is a report on FORM S-8' and provides a filename 'FORMS8ENLIVEX_isa.pdf'. Since the document is a brief announcement notifying the public of the filing of another document (Form S-8) rather than the report itself, it falls under the Report Publication Announcement (RPA) category.
2026-03-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.